KMT2A and acute leukemia: The benefit/risk assessment of the treatment of MLL-r acute leukemias with CAR-T cell therapy can only be fully assessed with more studies with a sufficient number of patients with these rearrangements, and by identifying possible differences among cytogenetic subgroups.